Outcomes of antiretroviral therapy in the swiss HIV cohort study: Latent class analysis

AIDS and Behavior

Volumn 16, Issue 2, 2012, Pages 245-255

  Keiser, Olivia ^a   Spycher, Ben ^a   Rauch, Andri ^a   Calmy, Alexandra ^b   Cavassini, Matthias ^c   Glass, Tracy R ^d   Nicca, Dunja ^e   Ledergerber, Bruno ^f   Egger, Matthias ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antiretroviral therapy; Behavior; Disease progression; HIV infection; Latent class analysis; Mortality; Social factors

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; ATTITUDE TO HEALTH; CLINICAL TRIAL; CLUSTER ANALYSIS; COHORT ANALYSIS; DISEASE TRANSMISSION; FEMALE; FOLLOW UP; HETEROSEXUALITY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; MIGRATION; MULTICENTER STUDY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; QUESTIONNAIRE; STATISTICS; SUBSTANCE ABUSE; SWITZERLAND; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; CLUSTER ANALYSIS; COHORT STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HETEROSEXUALITY; HIV SEROPOSITIVITY; HOMOSEXUALITY, MALE; HUMANS; LOST TO FOLLOW-UP; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; SUBSTANCE ABUSE, INTRAVENOUS; SWITZERLAND; TRANSIENTS AND MIGRANTS; TREATMENT OUTCOME;

EID: 84859699869     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-011-9971-5     Document Type: Article

References (42)

1. May MT, Sterne JA, Costagliola D, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet. 2006;368(9534):451-8.
2. Keiser O, Taffe P, Zwahlen M, et al. All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS. 2004;18(13):1835-43.
3. Zwahlen M, Harris R, May M, et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol. 2009;38(6):1624-33.
4. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet. 1999;353(9156):863-8.
5. Pellmar TC, Brandt EN Jr, Baird MA. Health and behavior: the interplay of biological, behavioral, and social influences: summary of an institute of medicine report. Am J Health Promot. 2002;16(4):206-19.
6. Wood E, Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300(5):550-4.
7. Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(Suppl 1):S19-25.
8. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214(2):231-41.
9. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365-71.
10. McMahon J, Wanke CA, Terrin N, Skinner S, Knox T. Poverty, hunger, education, and residential status impact survival in HIV. Aids Behavior. 2010. (in press).
11. Hogg R, Strathdee SA, Craib KJ, O'Shaughnessy MV, Montaner JS, Schechter MT. Lower socioeconomic status and shorter survival following HIV infection. Lancet. 1994;344(8939):1100-1.
12. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med. 1995;333(12):751-6.
13. Oramasionwu CU, Brown CM, Lawson KA, Ryan L, Frei CR. Evaluating HIV/AIDS disparities for blacks in the United States: a review of antiretroviral and mortality studies. J Natl Med Assoc. 2009;101(12):122-9.
14. McDavid Harrison K, Ling Q, Song R, Hall HI. County-level socioeconomic status and survival after HIV diagnosis, United States. Ann Epidemiol. 2008;18(12):919-27.
15. Katz MH, Hsu L, Lingo M, Woelffer G, Schwarcz SK. Impact of socioeconomic status on survival with AIDS. Am J Epidemiol. 1998;148(3):282-91.
16. Lazarsfeld R, Henry NW. Latent structure analysis. Latent structure analysis. Boston: Houghton Mifflin; 1968.
17. Spycher BD, Silverman M, Brooke AM, Minder CE, Kuehni CE. Distinguishing phenotypes of childhood wheeze and cough using latent class analysis. Eur Respir J. 2008;31(5):974-81.
18. Ganesalingam J, Stahl D, Wijesekera L, et al. Latent cluster analysis of ALS phenotypes identifies prognostically differing groups. PLoS One. 2009;4(9):e7107.
19. Girardi E, Angeletti C, Puro V, et al. Estimating diagnostic accuracy of tests for latent tuberculosis infection without a gold standard among healthcare workers. Euro Surveill. 2009;14(43):1-9.
20. Schoeni-Affolter F, Ledergerber B, Rickenbach M, et al. Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol. 2010;39(5): 1179-89.
21. Weber R, Huber M, Rickenbach M, et al. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV Med. 2009;10(7):407-16.
22. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41:1-20.
23. McLachlan G, Peel D. Finite mixture models. New York: John Wiley & Sons; 2000.
24. Rubin D. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987.
25. Gebhardt M, Rickenbach M, Egger M. Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland. Swiss HIV Cohort Study. AIDS. 1998;12(10):1195-201.
26. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10(3):227-45.
27. Glass TR, Battegay M, Cavassini M, et al. Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2010;54(2):197-203.
28. Greenland S, Gago-Dominguez M, Castelao JE. The value of riskfactor (''black-box'') epidemiology. Epidemiology. 2004;15(5): 529-35.
29. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009; 373(9672):1352-63.
30. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815-26.
31. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327): 119-29.
32. Braude HD. Clinical intuition versus statistics: different modes of tacit knowledge in clinical epidemiology and evidence-based medicine. Theor Med Bioeth. 2009;30(3):181-98.
33. Staehelin C, Keiser O, Calmy A, et al. Response to antiretroviral therapy in HIV-positive migrants of Sub-Saharan African origin within the Swiss HIV Cohort Study (SHCS). AIDS conference, Mexico 2008. Available at http://www.aids2008.org/Pag/Abstracts. aspx?SID=229&AID=6062. Accessed 5 May 2010.
34. Young J, De Geest S, Spirig R, et al. Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV Cohort Study. BMJ. 2004;328(7430):15.
35. Braitstein P, Brinkhof MWG, Dabis F, et al. Mortality of HIV-1- infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-24.
36. Lanoy E, Mary-Krause M, Tattevin P, et al. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther. 2007;12(1):89-96.
37. Battegay M, Fluckiger U, Hirschel B, Furrer H. Late presentation of HIV-infected individuals. Antivir Ther. 2007;12(6):841-51.
38. Wolbers M, Bucher HC, Furrer H, et al. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med. 2008;9(6):397-405.
39. Nellen JF, Wit FW, de Wolf F, Jurriaans S, Lange JM, Prins JM. Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands. J Acquir Immune Defic Syndr. 2004;36:943-50.
40. van den Berg JB, Hak E, Vervoort SC, et al. Increased risk of early virological failure in non-European HIV-1-infected patients in a Dutch cohort on highly active antiretroviral therapy. HIV Med. 2005;6(5):299-306.
41. World Health Organization. National AIDS programme management. Module 4. Targeted HIV prevention and care interventions. 2007.
42. Staehelin C, Egloff N, Rickenbach M, Kopp C, Furrer H. Migrants from sub-Saharan Africa in the Swiss HIV Cohort Study: a single center study of epidemiologic migration-specific and clinical features. AIDS Patient Care STDS. 2004;18(11): 665-75.